Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Verizon evp Kyle Malady sells $56,309 in company stock

Verizon evp Kyle Malady sells $56,309 in company stock

Executive Vice President and Group CEO-VZ Business of Verizon Communications Inc., Kyle Malady, sold 1,100 shares of the company's common stock for a total of $56,309 on September 15, 2026. The trade was carried out under a Rule 10b5-1 trading plan adopted by Mr. Malady on May 18, 2026. Post the transaction, Mr. Malady personally holds 105,466 shares of Verizon common stock, along with an additional 20,193 shares held indirectly through a 401(k) plan.

Despite Verizon stock trading at $46.36 on the day of the sale, which is lower than the sale price of $51.19, the insider sale did not raise eyebrows. The stock, according to InvestingPro, is deemed undervalued based on its Fair Value assessment. Verizon, a telecommunications giant with a market capitalization of $192 billion, provides investors with a 6.1% dividend yield, having increased its dividend for 22 consecutive years.

In its latest earnings report, Verizon surpassed Wall Street's earnings expectations with adjusted earnings per share (EPS) of $1.31, exceeding the estimated $1.28. However, the company's revenue fell short, recording $34.31 billion against the expected $34.77 billion. Despite the revenue shortfall, Verizon's earnings and subscriber growth led Freedom Broker to upgrade its stock rating to Buy, with a price target set at $55.

TD Cowen also maintained a Buy rating on Verizon, but adjusted its price target slightly downward to $55 due to SPCX concerns.

Both brokerage firms acknowledged Verizon's strong third-quarter performance, emphasizing increased phone additions and improved guidance. These developments underline Verizon's continuous efforts to enhance profitability and navigate evolving customer trends.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

Prediction: Visa Stock Hits $500 in 2028

The stock has been a standout in 2026, up 20% year to date.

  • Visa's revenue grew by 20% annually since 2026.
  • Cross-border transactions drove 13% of 2026 growth.
  • Analysts predict $17.14 per share by 2028.

One Hand-Typed Number Made My Drug Valuation 4.5x Too High

My drug valuation desk said a Phase 2 cancer drug was worth $1.29 billion. After two small fixes, the same drug with the same sales forecast was worth $283.5 million. Neither bug crashed anything.

  • Somota tool miscalculated drug valuation
  • Success rate typed manually, incorrect
  • 30% success rate led to $283.5M valuation

More from Sunday 15 November →